NASDAQ · TLSA
Healthcare · Biotechnology
$1.04
Up+$0.10 (+9.13%)
Updated Aug 14, 2026, 11:03 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
TLSA closed at $1.04 after 21 trading sessions, down 5.45% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $0.9891 | $1.09 | $0.9891 | $1.04 | 1.52M |
| Aug 12, 2026 | $1.01 | $1.01 | $0.9395 | $0.99 | 2.05M |
| Aug 11, 2026 | $1.01 | $1.01 | $0.97 | $1.01 | 414.69K |
| Aug 10, 2026 | $1.03 | $1.05 | $0.97 | $1.01 | 750.84K |
| Aug 7, 2026 | $0.988 | $1.03 | $0.9564 | $1.00 | 982.25K |
| Aug 6, 2026 | $1.02 | $1.10 | $0.972 | $0.9743 | 1.99M |
| Aug 5, 2026 | $0.9676 | $1.079 | $0.9501 | $0.99 | 984.97K |
| Aug 4, 2026 | $0.9441 | $1.02 | $0.9441 | $0.9676 | 577.91K |
| Aug 3, 2026 | $1.00 | $1.11 | $0.8898 | $0.9693 | 3.01M |
| Jul 31, 2026 | $1.00 | $1.15 | $0.98 | $1.03 | 388.47K |
| Jul 30, 2026 | $0.9546 | $1.01 | $0.9546 | $0.97 | 15.33K |
| Jul 29, 2026 | $0.9623 | $1.02 | $0.94 | $0.9588 | 56.11K |
| Jul 28, 2026 | $0.9173 | $0.9847 | $0.90 | $0.9672 | 266.08K |
| Jul 27, 2026 | $0.9328 | $0.9459 | $0.91 | $0.9102 | 114.56K |
| Jul 24, 2026 | $0.99 | $1.0199 | $0.8663 | $0.8925 | 328.81K |
| Jul 23, 2026 | $0.95 | $1.02 | $0.9099 | $1.02 | 490.5K |
| Jul 22, 2026 | $1.09 | $1.09 | $0.9101 | $0.945 | 418.82K |
| Jul 21, 2026 | $1.04 | $1.04 | $0.9105 | $1.00 | 341.04K |
| Jul 20, 2026 | $1.08 | $1.12 | $0.9947 | $1.015 | 215.61K |
| Jul 17, 2026 | $1.10 | $1.12 | $1.06 | $1.07 | 140.81K |
| Jul 16, 2026 | $1.12 | $1.17 | $1.10 | $1.10 | 225.28K |
The latest Smart Investors Daily articles mentioning TLSA.
TLSA research
Company profile and research snapshot.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 13, 2022 | ThinkEquity | Buy | — |
| Apr 12, 2021 | Zacks Investment Research | Not Rated | — |
| Sep 21, 2020 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 31, 2026
Tiziana Life Sciences reports reduced brain inflammation in its third Phase 2 trial patient treated with intranasal foralumab for MSA.
Benzinga · Jul 31, 2026
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces quantitative PET imaging
Benzinga · Jun 25, 2026
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Progressive Multiple
Yahoo · Jun 15, 2026
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TLSA.
No results
No recent SID articles mention TLSA.
